Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Author(s): Silas Ramos Furquim , Maria Tereza Sampaio de Sousa Lira , Deborah de Sá Pereira Belfort , et al Added: 4 months ago

Guidelines & Statements

Heart Failure
Guideline-directed Medical Therapy is the Most Effective Decongestion
Author(s): Jelena Celutkiene , Alexandre Mebazaa , Jan Biegus , et al Added: 1 year ago

Heart Failure
Polygenic Risk Score Independently Predicts New-Onset Heart Failure
Added: 7 months ago Source:  Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 9 months ago

Heart Failure
FDA Approves Finerenone for Heart Failure with LVEF ≥40%
Added: 8 months ago Source:  Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The… View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
Late-Breaking Clinical Trial Presentations for Heart Failure Congress 2024 Revealed
Added: 1 year ago Source:  Heart Failure 2024
Heart Failure Congress 2024 has unveiled 8 Late-breaking trial sessions for 2024.Heart Failure 2024 will take place at the Lisbon Congress Center in May. Access the full Programme here.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators, and keep up to date with our Late-Breaker Discussions with Dr Van Spall.Late… View more

Heart Failure
Evidence-Based Approaches to Optimising Treatment Outcome
Author(s): Javed Butler , Shelley Zieroth , Gianluigi Savarese Added: 1 year ago
Radcliffe Medical Education, is proud to bring to you this roundtable series which is designed to equip healthcare professionals with the knowledge and tools necessary to identify high-risk patients indicative of worsening HF and to implement effective management strategies. Watch Dr Javed Butler (Baylor Scott & White Health, Dallas, US); Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA)… View more

Heart Failure
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Author(s): Dung Viet Nguyen , Hoai Thi Thu Nguyen Added: 6 months ago

Heart Failure
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 5 months ago

Heart Failure
Simple Risk Stratification Could Optimise Heart Failure Follow-Up and Outcomes
Added: 8 months ago Source:  Radcliffe Cardiology
A new nationwide cohort study from France suggests that a simple risk stratification tool based on administrative data could help tailor cardiologist follow-up for patients with heart failure (HF), potentially improving survival and optimising resource use. The study found that 40% of patients with HF do not have an annual cardiology consultation, regardless of their disease severity.¹The French… View more

Digital Health

Guidelines & Statements